Trials / Completed
CompletedNCT04087525
A Study to Evaluate the Pharmacokinetics and Safety of HIP1701 in Healthy Subjects
A Randomized, Open-Label, Single-Dose, Two-way Crossover Study to Compare Pharmacokinetic Properties and Safety of HIP1701 and HGP1809 in Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics and safety of HIP1701 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HIP1701 | Vildagliptin |
| DRUG | HGP1809 | Vildagliptin |
Timeline
- Start date
- 2018-10-23
- Primary completion
- 2018-11-27
- Completion
- 2018-11-27
- First posted
- 2019-09-12
- Last updated
- 2019-09-12
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04087525. Inclusion in this directory is not an endorsement.